Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
4D Molecular Therapeutics Inc
(NQ:
FDMT
)
15.25
-0.05 (-0.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about 4D Molecular Therapeutics Inc
< Previous
1
2
3
Next >
4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
August 27, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 12, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights
August 08, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board
August 05, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
July 29, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
July 21, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
July 17, 2024
From
The Schall Law Firm
Via
Business Wire
4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity
July 17, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
June 24, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
June 18, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
June 08, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
June 06, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting
June 04, 2024
• 24-week injection-free subgroup analyses from the Randomized Phase 2 Dose Expansion Stage of PRISM Trial Evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden...
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
June 03, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference
May 30, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
May 09, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Participate in Upcoming Investor Conference
May 07, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Announces Presentations at ARVO 2024 Annual Meeting
May 01, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
March 28, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
March 04, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
February 29, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
February 12, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
February 06, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
February 05, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4D Molecular Therapeutics Inc. (NASDAQ: FDMT) Leading the Way in Monday Trading Based on Percentage Gain
February 05, 2024
Via
Investor Brand Network
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
February 03, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
January 29, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
January 23, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates
January 04, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
January 03, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.